Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 19 of 19 publications.

Dave RH, Crayton H, Miravalle A, Tai MH, Wyse K, Houghton K, Hitchens A, Berkovich R. COVID-19 vaccination response in patients with multiple sclerosis treated with ofatumumab in the United States: a medical record review. Neurol Ther. 2024 Oct 23. doi: 10.1007/s40120-024-00671-0

Barrett A, Olayinka-Amao O, Ziemssen T, Bharadia T, Henke C, Kamudoni P. Understanding the symptoms and impacts experienced by people with relapsing-remitting MS: a qualitative investigation using semi-structured interviews. Neurol Ther. 2024 Apr;13(2):449-64. doi: 10.1007/s40120-024-00584-y

Callahan LF, Samsell B, DiBenedetti D, Frangiosa T, Slota C, Biggar V, Paulsen R, Lappin D, Herring WL, Romano (DeMuro) C. Evaluating elements of the care partner experience in individuals who care for people with Alzheimer's disease across the severity spectrum. Neurol Ther. 2024 Feb;13(1):53-67. doi: 10.1007/s40120-023-00558-6

Tahami Monfared AA, Phan NTN, Pearson I, Mauskopf J, Cho M, Zhang Q, Hampel H. A systematic review of clinical practice guidelines for Alzheimer's disease and strategies for future advancements. Neurol Ther. 2023 Aug;12(4):1257-84. doi: 10.1007/s40120-023-00504-6

Anderson-Smits C, Ritchey ME, Huang Z, Chavan S, Souayah N, Ay H, Layton BJ. Intravenous immunoglobulin treatment patterns and outcomes in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a US claims database analysis. Neurol Ther. 2023 Aug;12(4):1119-32. doi: 10.1007/s40120-023-00478-5

Layton JB, Ritchey ME, Huang Z, Chavan S, Ay H, Souayah N, Anderson-Smits C. Intravenous immunoglobulin initiation in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a US claims-based cohort study. Neurol Ther. 2023 Aug;12(4):1171-86. doi: 10.1007/s40120-023-00479-4

Hauber B, Paulsen R, Krasa HB, Vradenburg G, Comer M, Callahan LF, Winfield J, Potashman M, Hartry A, Lee D, Wilson H, Hoffman DL, Weiberg D, Kremer IN, Taylor GA, Taylor JM, Lappin D, Martin AD, Frangiosa T, Biggar V, Slota C, Romano (DeMuro) C, DiBenedetti D. Assessing what matters to people affected by Alzheimer's disease: a quantitative analysis. Neurol Ther. 2023 Apr;12(2):505-27. doi: 10.1007/s40120-023-00445-0

DiBenedetti D, Menne H, Paulsen R, Krasa HB, Vradenburg G, Comer M, Callahan LF, Winfield J, Potashman M, Heithoff K, Hartry A, Oberdhan D, Wilson H, Hoffman DL, Weinberg D, Kremer IN, Taylor GA, Taylor JM, Lappin D, Martin AD, Hauber B, Romano (DeMuro) C. Technical review of clinical outcomes assessments across the continuum of Alzheimer's disease. Neurol Ther. 2023 Apr;12(2):571-95. doi: 10.1007/s40120-023-00443-2

Forns J, Dudukina E, Hagg D, Szentkuti P, Gembert K, Plana E, Gilsenan A, Horvath-Puho E, Ehrenstein V, Reutfors J, Rebordosa C. Risk of major cardiovascular and cerebrovascular events in users of lisdexamfetamine and other medications for attention-deficit/hyperactivity disorder in Denmark and Sweden: a population-based cohort study. Neurol Ther. 2022 Dec 1;11(4):1659-76. doi: 10.1007/s40120-022-00396-y

Tahami Monfared AA, Houghton K, Zhang Q, Mauskopf J, Alzheimer’s Disease Neuroimaging Initiative. Published Erratum - Correction to: Staging disease severity using the Alzheimer's Disease Composite Score (ADCOMS): a retrospective data analysis. Neurol Ther. 2022 Jun;11(2):915-27. doi: 10.1007/s40120-022-00340-0

Tahami Monfared AA, Houghton K, Zhang Q, Mauskopf J, Alzheimer’s Disease Neuroimaging Initiative. Staging disease severity using the Alzheimer's disease composite score (ADCOMS): a retrospective data analysis. Neurol Ther. 2022 Mar;11(1):413-34. doi: 10.1007/s40120-022-00326-y

Lewis S, Wray SE, Evans E, Romano (DeMuro) C, Bartolome L, Su W, Shah R, Russo PA. Patients' experiences in transitioning to secondary progressive multiple sclerosis: qualitative interviews. Neurol Ther. 2021 Dec;10(2):887-904. doi: 10.1007/s40120-021-00265-0

Herring WL, Gould IG, Fillit H, Lindgren P, Forrestal F, Thompson R, Pemberton-Ross P. Predicted lifetime health outcomes for aducanumab in patients with early Alzheimer's disease. Neurol Ther. 2021 Dec;10(2):919-40. doi: 10.1007/s40120-021-00273-0

Li W, Zou T, Li L, Deng Y, Sun VT, Zhang Q, Layton B, Setoguchi S. Impacts of the North Atlantic subtropical high on interannual variation of summertime heat stress over the conterminous United States. Clim Dyn. 2019 Sep;53(5-6):3345-59. doi: 10.1007/s00382-019-04708-1

Houghton DE, Alsawas M, Barrioneuvo P, Tello M, Farah W, Beuschel B, Prokop LJ, Layton JB, Murad MH, Moll S. Testosterone therapy and venous thromboembolism: a systematic review and meta-analysis. Thromb Res. 2018 Dec;172:94-103. doi: 10.1016/j.thromres.2018.10.023

Julvez J, Paus T, Bellinger D, Eskenazi B, Tiemeier H, Pearce N, Ritz B, White T, Ramchandani P, Gispert JD, Desrivieres S, Brouwer R, Boucher O, Alemany S, Lopez-Vicente M, Suades-Gonzalez E, Forns J, Grandjean P, Sunyer J. Environment and brain development: challenges in the global context. Neuroepidemiology. 2016;46(2):79-82. doi: 10.1159/000442256

Forns J, Aranbarri A, Grellier J, Julvez J, Vrijheid M, Sunyer J. A conceptual framework in the study of neuropsychological development in epidemiological studies. Neuroepidemiology. 2012 Jun;38(4):203-8. doi: 10.1159/000337169

Doward LC, McKenna SP, Meads DM, Jovell AJ, Fisk J, Eckert BJ. The international development of patient reported outcome indices for multiple sclerosis. Poster presented at the 2006 Sixteenth Meeting of the European Neurological Society; May 2006. Lausanne, Switzerland. [abstract] J Neurol. 2006; 253(Suppl 2):125.

Fischer T, Johnsen SP, Pedersen L, Gaist D, Sorensen HT, Rothman KJ. Seasonal variation in hospitalization and case fatality of subarachnoid hemorrhage - A nationwide Danish study on 9,367 patients. Neuroepidemiology. 2005 Jan 1;24(1-2):32-7.